Company Overview and News

51
Cigna’s Merger With Express Scripts Is Positive for Cigna Stock

11h investorplace
Federal officials finally approved the merger of Cigna (NYSE:CI), one of the nation’s biggest health insurers, and pharmacy benefit manager Express Scripts Holding Co. (NASDAQ:ESRX) Cigna stock has been a strong performer in recent years, and this merger will make CI stock even more formidable.
AMZN CI CVS AET ESRX

7
CI / Cigna Corp. CIGNA CORPORATION FORM 8-K (Current Report)

2018-09-21 sec.gov - 1
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K
CI

7
Humana (HUM) Expands Pact With Fitbit to Rein in Claim Cost

2018-09-20 zacks
Health insurer Humana Inc. (HUM - Free Report) has extended its partnership (since 2013) with Fitbit, Inc. (FIT - Free Report) , the leading global wearables brand. The arrangement between the two companies will aid Humana’s members in the employer group segment to adopt and implement healthy behaviors, which in turn would prevent and manage chronic health conditions. Fitbit’s health coaching solution named Fitbit Care, will help more than 5 million Humana members access ways to make necessary lifestyle changes in order to better manage chronic and complex diseases such as diabetes and heart disease.
ATHTF FIT CI ANTM LB HUM ANTX

51
What Cigna Investors Should Expect From Its Latest Victory

2018-09-19 investorplace
Cigna (NYSE:CI) was recently granted an early termination of the antitrust waiting period by the U.S. Department of Justice (DOJ) for its proposed acquisition of pharmacy benefit manager Express Scripts (NASDAQ:ESRX). With this, Cigna has managed to cross a major hurdle in the path of this deal. Notably, this transaction had received friction from CI stock investor Carl Icahn, who urged the shareholders of the companies involved to vote against the deal on concerns that it would hardly benefit Cigna, given the headwinds faced by Express Scripts.
AMZN CI CVS AET ESRX

20
Cigna Moves Closer to Express Scripts Buyout With DoJ Nod

2018-09-18 zacks
Cigna Corp. (CI - Free Report) was recently granted an early termination of the antitrust waiting period by the U.S. Department of Justice (DOJ) for its proposed acquisition of pharmacy benefit manager Express Scripts Holding Co. (ESRX - Free Report) . With this, Cigna has managed to cross a major hurdle in the path of this deal.
TXN MDPEB CI MDP CVS AET

12
8 GARP Stocks to Scoop Up for Maximum Returns

2018-09-18 zacks
Growth at a reasonable price or GARP is an excellent way for investors to make some quick gains. This strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. The GARP approach leads to the identification of stocks that are priced below the market or any reasonable target determined by fundamental analysis. These stocks also have solid prospects in terms of cash flow, revenues, earnings per share (EPS) and so on.
AFW TXN AFGE AFA MDP AFGH EME TER AFG CBG LAZ MDPEB CI MXIM CBRE CE

18
More Changes to the Pharmacy Industry Coming as DOJ Approves Cigna-Express Scripts Deal

2018-09-18 biospace
In March, U.S. insurer CIGNA Corporation announced it was acquiring pharmacy benefits manager Express Scripts for approximately $52 billion. On Monday, the Department of Justice (DOJ) approved the merger.
BRK.A NYTAB CI CVS

6
PRESS DIGEST- New York Times business news - Sept 18

2018-09-18 reuters
Sept 18 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
NYTAB CI

10
PRESS DIGEST -Wall Street Journal - Sept 18

2018-09-18 reuters
Sept 18 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
TSNU GOOGL AAPL FDX GOOG CI TSN

20
Cigna deal gets antitrust nod, positive sign for CVS/Aetna

2018-09-17 reuters
(Reuters) - Health insurer Cigna Corp’s (CI.N) $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
ATHTF BRK.A TWX ANTM CI CVS TWC HUM AET ANTX

20
Cigna-Express Scripts deal gets US antitrust approval

2018-09-17 channelnewsasia
Health insurer Cigna Corp's US$52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
ATHTF BRK.A TWX ANTM CI CVS TWC HUM AET ANTX

6
CI / Cigna Corp. CIGNA CORPORATION FORM 8-K (Prospectus)

2018-09-17 sec.gov
UNITED STATES SECURITIES AND EXCHAN
CI

6
CI / Cigna Corp. CIGNA CORPORATION FORM 8-K (Current Report)

2018-09-17 sec.gov
UNITED STATES SECURITIES AND EXCHAN
CI

15
UPDATE 1-Cigna-Express Scripts deal gets U.S. antitrust approval

2018-09-17 reuters
(Reuters) - Health insurer Cigna Corp’s (CI.N) $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
CI CVS AET

6
Cigna-Express scripts deal gets anti-trust approval

2018-09-17 reuters
Health insurer Cigna Corp’s $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing a combination the companies say will lead to lower costs by better coordinating pharmacy and medical benefits.
CI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CI / Cigna Corp. on message board site Silicon Investor.

The Financial Collapse of 2001 Unwinding The Financial Collapse of 2001 Unwinding The Financial Collapse of 2001 Unwinding Laughter is the Best Medicine - Tell us a joke Laughter is the Best Medicine - Tell us a joke Laughter is the Best Medicine - Tell us a joke
Robotics and Artificial Intelligence Robotics and Artificial Intelligence Robotics and Artificial Intelligence A Review of TV Commercials: The Good, The Bad, u0026 The Ugly A Review of TV Commercials: The Good, The Bad, u0026 The Ugly A Review of TV Commercials: The Good, The Bad, u0026 The Ugly
Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing Gardening and Especially Tomato Growing [email protected] u0026 TRUTHSEEKER Expose Crims u0026 Scammers!!! [email protected] u0026 TRUTHSEEKER Expose Crims u0026 Scammers!!! [email protected] u0026 TRUTHSEEKER Expose Crims u0026 Scammers!!!
Specially made small condoms for Soy Boy Libtards Specially made small condoms for Soy Boy Libtards Specially made small condoms for Soy Boy Libtards NNVC - NanoViricides, Inc. NNVC - NanoViricides, Inc. NNVC - NanoViricides, Inc.
Socialized Education - Is there abetter way? Socialized Education - Is there abetter way? Socialized Education - Is there abetter way? PAW - Pacific Wildcat Resources Corp PAW - Pacific Wildcat Resources Corp PAW - Pacific Wildcat Resources Corp
CUSIP: 125509109